Akero Therapeutics, Inc. (AKRO) Financials

AKRO Assets vs Liabilities

DateAssetsLiabilities
Dec. 31, 2023 580.3 million 45.0 million
Sept. 30, 2023 635.3 million 52.2 million
June 30, 2023 663.8 million 47.4 million
March 31, 2023 348.8 million 42.5 million

AKRO Free Cash Flow and Stock based compensation

Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Dec. 31, 2023 -48.6 million 6.1 million
Sept. 30, 2023 -49.7 million 5.7 million
June 30, 2023 -22.4 million 4.8 million
March 31, 2023 -24.6 million 4.8 million

AKRO Net Income

No data available :(

AKRO Cash and Debt

Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Dec. 31, 2023 550.0 million - 1.3 million
Sept. 30, 2023 554.7 million - 1.4 million
June 30, 2023 639.4 million - 1.4 million
March 31, 2023 343.2 million 24.6 million 1.4 million

AKRO Shares Outstanding

Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Dec. 31, 2023 55.7 million
Sept. 30, 2023 55.6 million
June 30, 2023 51.9 million
March 31, 2023 46.9 million

AKRO Expenses

Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Dec. 31, 2023 - 53.4 million 8.5 million 2000
Sept. 30, 2023 - 38.6 million 8.0 million -
June 30, 2023 - 28.0 million 7.6 million -
March 31, 2023 - 21.8 million 7.0 million -

AKRO Cost of Revenue

Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Dec. 31, 2023 284000 2000
Sept. 30, 2023 - 5000
June 30, 2023 - 69000
March 31, 2023 - 68000

AKRO

Price: $54.65

52 week price:
21.34
58.40

Earnings Per Share: -3.75 USD

P/E Ratio: -14.52

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 143289

Market Capitalization: 4.5 billion

Links: